| Discover Algeria | About us | Press area | Contact |
-
Legal INVEST
Les derniers textes juridiques
View more
Les interviews By AlgeriaInvest
Newsletter
Subscribe to the economic newsletter
- News
NEW NEWS
- Our Services
- News
October 15, 2025 | 2 months ago
Agreement between Saidal and Novo Nordisk: Latest-generation insulin coming soon
Good news for diabetics in Algeria. Local development of innovative treatments is accelerating with the upcoming production of the latest-generation insulin, which will be developed and distributed in the country.
A strategic agreement has
been signed between the Algerian public pharmaceutical group Saidal and the
local subsidiary of Danish giant Novo Nordisk Algeria. This ambitious
partnership aims to jointly develop the production and distribution of
innovative molecules, particularly the latest generation of insulins. These
treatments, which are vital for people with diabetes, mark a significant
advance in healthcare in Algeria.
According to specialists, nearly 4 million Algerians are affected by diabetes,
1.5 million of whom require insulin treatment. The local production of this
molecule, its diversification, and its improvement therefore represent a major
challenge for the country's health sovereignty.
For several years, Algeria has been committed to a policy of reducing its dependence on imported medicines, focusing on the local manufacturing of essential products, including vaccines, anti-cancer drugs, and insulin. The Minister of Health recently reaffirmed this strategy before the National People's Assembly, emphasizing the desire to remove administrative barriers, support export projects, and strengthen research in collaboration with universities and start-ups.
The signing of the
agreement between Saidal and Novo Nordisk Algeria, in the presence of the
leaders of both companies, marks a significant step toward establishing a
comprehensive aseptic production facility in Algeria. This partnership is based
on the transfer of technology and expertise, to ensure Algerian patients have
greater access to innovative, safe treatments that meet international
standards.
By combining Novo Nordisk's global expertise in research and development with
Saidal's industrial roots in the national pharmaceutical sector, this project
promises to strengthen local production capacities in the long term and
actively contribute to the country's health sovereignty. The project will be
implemented in collaboration with the Ministry of Health and the National
Health Insurance Fund. The project will be implemented in collaborating with
the Ministry of Health and the National Health Insurance Fund.
October 15, 2025 | 
Popular Articles
